SCHEDULE: Janus Henderson Discloses 12.2% Stake in CAMP4 Therapeutics

Janus Henderson Group plc has reported a 12.2% beneficial ownership stake in CAMP4 THERAPEUTICS CORP, as detailed in a recent Schedule 13G filing.

Summary

• Janus Henderson Group plc, an investment adviser and parent holding company, has filed a Schedule 13G indicating beneficial ownership in CAMP4 THERAPEUTICS CORP.
• The reporting person beneficially owns 6,307,636 shares of Common Stock in CAMP4 THERAPEUTICS CORP.
• This ownership represents 12.2% of the class of securities.
• Janus Henderson Group plc holds shared voting power and shared dispositive power over all 6,307,636 shares.
• JHIUS may also be deemed the beneficial owner of an additional 1,241,382 pre-funded warrants, which cannot be exercised to the extent they result in ownership exceeding 9.99%.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Janus Henderson Enterprise Fund, an investment company registered under the Investment Company Act of 1940, holds 1,230,753 shares or 5.0% of ICU Medical Common Stock.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain subjective information to assess sentiment beyond the neutral act of reporting a stake.

Positives

• A significant institutional investor, Janus Henderson Group plc, holds a substantial stake (12.2%) in CAMP4 THERAPEUTICS CORP, which can be interpreted as a vote of confidence.
• The filing explicitly states the holding is for ordinary course of business, not for control, indicating a passive investment intent.

Risks

• The Schedule 13G filing itself does not detail specific risks for CAMP4 THERAPEUTICS CORP, as it is primarily a disclosure of passive ownership.

Industry Context

This filing indicates a significant institutional investment firm, Janus Henderson Group plc, has taken a substantial passive stake in CAMP4 THERAPEUTICS CORP, a common practice for investment advisers managing diversified portfolios. Such disclosures provide transparency into institutional holdings within the biotechnology or pharmaceutical sector, where CAMP4 likely operates given its name.

Related Party Transactions

• Janus Henderson Enterprise Fund, an investment company registered under the Investment Company Act of 1940 and a related entity to Janus Henderson Group plc, holds 1,230,753 shares or 5.0% of ICU Medical Common Stock.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder, which could be viewed positively as a vote of confidence or simply as a disclosure of a large passive stake.
• Management: Awareness of a large institutional shareholder, though the filing states no intent to influence control.

Key Dates

Keywords

CAMP4 THERAPEUTICS CORP, Janus Henderson Group plc, Schedule 13G, beneficial ownership, institutional investor, common stock, investment adviser, parent holding company, equity stake